re: trials / gdb....sbp is unique stolwyk,Well done on a good...

re: trials / gdb....sbp is unique stolwyk,

Well done on a good post.

In spite of any mistakes SBP management have made or may make, I believe the Board genuinely have the interests of SBP and its shareholders as their priority.

The fact remains that SBP have a natural product that has at these early stages proven to be effective on a broad range of cancers, is relatively non-toxic to normal cells, boosts the immune system, appears to enhance the general well-being of the patient, has diagnostic potential and has already yielded encouraging results on Special Access Scheme patients.

Therefore it would appear likely that positive results may well be obtained from the recently commenced formal human trials, and that if SBP002 can prove beneficial in the treatment of mesothelioma, the approval process can be expeditiously completed.(ie. Orphan Drug Status)

With a market cap. fully diluted of approx. $30m, SBP's upside potential could be enormous.

Any views??